MDMA Therapy FDA Decision, What the Rejection Letter Means for Seekers

In September 2025, the FDA made two significant moves at once. It announced a new policy requiring public release of Complete Response Letters in real time. And it published a backlog of 89 previously withheld letters, including the one sent to Lykos Therapeutics rejecting their application for MDMA-assisted therapy for post-traumatic stress disorder.

For anyone following the psychedelic medicine space, the CRL had been known since 2024. What was not known was the detailed reasoning behind it. That reasoning is now public record.

At JourneyŌM, we think this moment deserves a clear read. Not alarm, not dismissal. Just an honest look at what the FDA found, what it means for the field, and what seekers should actually take away from it.

What is a Complete Response Letter?

A Complete Response Letter is the FDA’s formal written response to a drug sponsor when an application cannot be approved as submitted. It details the specific deficiencies that need to be resolved before the agency will reconsider.

CRLs are not final rejections. They are documented lists of unresolved concerns. A sponsor can address those concerns and resubmit. But the letter is a serious document, and the FDA’s new policy of publishing them publicly changes the stakes considerably.

Until September 2025, CRLs were largely kept private between the FDA and the sponsor. Now they are released in real time. The practical effect is that the entire field, including researchers, investors, advocacy organizations, and the public, can see exactly where and why an application fell short.

What the FDA found in the Lykos application

The Lykos CRL identified three core areas of concern. Each one is worth understanding on its own terms.

1. Safety data gaps and potential underreporting

The FDA raised concerns about how adverse events were captured and reported across trial sites. The issue is not that MDMA caused obvious harm that was covered up. The issue is that the agency did not have sufficient confidence that all safety signals had been fully identified, documented, and disclosed. The FDA requested an independent data audit as a condition of resubmission.

This matters because a drug seeking federal approval for a serious psychiatric condition needs a complete safety picture. Partial or inconsistently reported data cannot support that standard, regardless of how promising the outcomes appear.

2. Insufficient evidence of durability

PTSD is a chronic condition. The FDA’s concern is straightforward: showing that participants felt better for several months after treatment is not the same as showing that the treatment works over the long term. The trial data did not adequately demonstrate that the benefits observed were sustained well beyond the treatment window.

For a chronic disorder, durability is not a secondary question. It is central to the approval case.

3. Trial selection concerns

A high proportion of trial participants had prior experience with MDMA. The FDA raised this as a potential source of bias. People who already have positive associations with a substance may respond differently from a general patient population with no prior exposure. This affects how well the results generalize, and it is a legitimate methodological concern that future trials will need to address directly.

Safety first: What this means for the field

The FDA’s concerns in the Lykos CRL reflect something broader than one application. They signal the evidentiary standard the agency expects for psychedelic-assisted therapies moving forward.

The psychedelic field has grown rapidly, and some of that growth has outpaced the rigor needed to meet regulatory standards. Promising outcomes in early trials generated significant enthusiasm. But enthusiasm is not the same as complete, auditable, durable evidence.

The FDA is not saying MDMA therapy cannot work. It is saying the submitted evidence did not yet meet the bar required to support approval for a chronic psychiatric disorder in a general patient population. That is a meaningful distinction.

MAPS, the advocacy organization behind much of the early MDMA research, praised the FDA’s transparency while arguing that the goalposts had shifted after trial completion and that delays hurt patients living with PTSD. That tension reflects a real challenge in the field: when standards evolve mid-process, sponsors face genuine uncertainty. At the same time, the FDA’s responsibility is to ensure the evidence is sufficient, not to approve on the strength of optimism.

What this means for you as a seeker

If you are exploring psychedelic-assisted support, the Lykos CRL is not a reason to abandon your inquiry. It is a reason to be more informed about what is and is not currently established.

Here is what the current landscape actually looks like. There are no federally approved psychedelic medicines for psychotherapy as of early 2026. MDMA-assisted therapy for PTSD did not receive FDA approval. Psilocybin is available in state-regulated frameworks in Oregon and Colorado, but outside a clinical approval context. Ketamine is legally available and widely used, though the evidence base for its long-term efficacy varies by condition and context.

This is where clarity matters more than enthusiasm. The regulatory picture is evolving. What is available now is not the same as what may be available in three years. And the FDA’s new transparency policy means that the reasoning behind approvals and rejections will be increasingly visible to everyone, which is useful information for anyone making decisions in this space.

A few grounded questions worth sitting with:

• What kind of support are you actually looking for, and is it currently available within a legal, professionally guided framework?
• Do you understand the difference between state-regulated access and federally approved treatment?
• Are you working with someone who can help you assess readiness, risk, and realistic expectations?

Why integration still matters here

One of the underexamined aspects of the Lykos CRL is the durability question, and it connects directly to integration. The FDA wanted evidence that benefits lasted. That is a regulatory standard. But it also reflects something that guides and experienced practitioners have long understood: the experience itself is not the endpoint.

What happens in the weeks and months after a psychedelic experience often determines how much of it actually lands in a person’s life. Insight without support tends to fade. Emotional openings without integration can leave people disoriented rather than changed. The field’s regulatory challenges and the practical needs of seekers are pointing at the same thing from different directions.

Integration is not a product add-on. It is part of what makes psychedelic-assisted work meaningful and sustainable over time.

Key takeaways

• The FDA rejected the Lykos MDMA therapy application citing safety data gaps, insufficient durability evidence, and trial selection concerns
• The FDA now publicly releases Complete Response Letters, which increases transparency but also raises the stakes for every sponsor in the psychedelic space
• No psychedelic medicine is currently federally approved for psychotherapy in the United States
• The rejection does not mean MDMA therapy cannot eventually be approved, but resubmission will require stronger evidence on all three fronts
• For seekers, this is a reason to be more informed and more careful, not to disengage from the conversation
• Durability concerns reinforce why integration is not optional in well-supported psychedelic work